Peptide Science Desk

Novo Nordisk Q3 2026: Wegovy pill sales and a raised outlook — what it means

November 5, 2026By the Peptide Science Desk Editorial TeamFact-checked against FDA and official sources · Not yet reviewed by a licensed clinician. How we check facts

In short: on November 4, 2026 Novo Nordisk posted first-nine-months / Q3 results. Q3 adjusted sales were DKK 79.2 billion (+4% at constant exchange rates). Full-year 2026 outlook for adjusted sales and operating-profit growth was raised to −2% to +2% CER (from −6% to 0%). The Wegovy pill had more than 8 million cumulative U.S. prescriptions since launch. CagriSema is still not FDA approved; Novo guides a U.S. decision in Q4 2026 and, if approved, a launch early 2027. This is earnings and pipeline guidance — not an FDA approval. GLP-1 price tracker · Cagrilintide / CagriSema
A pharmacist in a white coat looks at a bottle of liquid medicine in front of shelves

1. What Novo reported

  • Q3 sales and profit. Adjusted sales DKK 79.2 bn (+4% CER); adjusted operating profit DKK 31.7 bn. Novo financial results page, investor presentation PDF, CNBC summary.
  • Outlook raised. Full-year 2026 adjusted sales and adjusted operating-profit growth: −2% to +2% CER (prior guidance −6% to 0%).
  • Wegovy pill volume. Novo’s PDF shows >8 million cumulative U.S. prescriptions since launch, about 80% of new-to-brand oral obesity prescriptions, and about 20% sequential pill volume growth in Q3 vs Q2. CNBC reported Novo’s Wegovy pill Q3 sales at about DKK 5.4 billion.

2. What did not change

  • CagriSema is still investigational. The PDF says CagriSema is pending U.S. regulatory approval, with an FDA decision expected in Q4 2026 and a U.S. launch planned early 2027 subject to approval. REDEFINE 9 and REIMAGINE 5 are phase 3 trial updates — not approvals.
  • List price vs self-pay. Novo’s separate plan for a $675/month list price for Wegovy, Ozempic and Rybelsus from Jan 1, 2027 is unchanged by this earnings release and is not the same as maker self-pay cash prices. See the price tracker.
  • Medicare Bridge. The CMS Medicare GLP-1 Bridge ($50/month through Dec 31, 2027 for qualifying people) is a CMS program. Novo materials mention Bridge / NovoCare uptake; that does not rewrite your plan’s formulary.
  • Unapproved “research” copies are still not the approved pill.

3. Related

Check any peptide in 1 secondFree FDA Status Checker: approved, being tested, or not proven.

Not medical advice. Medical disclaimer.